Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.71
    +0.10 (+0.26%)

    Market Cap: $28.64B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Roivant Sciences Ltd (ROIV) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Roivant Sciences (ROIV) has a market cap of $28.64B and an enterprise value of $27.00B. It kept -939.03% of revenue as net income over the last 12 months. Revenue grew 102.09% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 5.73% below the market cap, as cash exceeds debt.

    Market Cap$28.64B
    Enterprise Value$27.00B
    Latest price (Nov 17, 2026)$38.71

    Key Dates

    Last Earnings DateNov 9, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 0.27% in the quarter ended Sep 30, 2026 and shrank 0.87% a year over 2 years.

    Shares Outstanding722.75M
    Shares Change (YoY)+6.14%
    Shares Change (QoQ)+0.27%
    Share Count Growth (2Y CAGR)-0.87%

    Valuation Ratios

    Sales and book value multiples are 681.0x and 7.0x. Its year-end P/S ranged from 110.8x to 612.8x from 2021 to 2024.

    P/S Ratio681.0x
    Forward P/S173.3x
    P/B Ratio7.0x

    Valuation history and multiples

    Price Statistics

    The stock is up 90.78% over 52 weeks and trades 3.72% above its 50-day average.

    Beta (1Y)1.12
    52-Week Change+90.78%
    1-Month Change+11.56%
    3-Month Change+3.50%
    6-Month Change+37.22%
    5-Year Change+364.86%
    Total Return (1Y)+90.78%
    Total Return (3Y CAGR)+62.79%
    Total Return (5Y CAGR)+36.69%
    Return vs SPY (1Y)+77.09%
    Max Drawdown (1Y)-20.23%
    Max Drawdown (3Y)-28.56%
    Sharpe Ratio (1Y)1.39
    Correlation with SPY (1Y)0.34
    50-Day Average$37.32
    200-Day Average$32.48
    52-Week Range$19.96 to $42.50
    RSI (14 Days)53.5
    Average Volume (20 Days)8.97M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 15.56x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio15.56x
    Quick Ratio15.56x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -9.60% over the last 12 months, against a 5-year average of -19.53%.

    Return on Equity (ROE)-9.60%
    Return on Assets (ROA)-7.75%
    ROE (5Y Average)-19.53%
    ROA (5Y Average)-7.47%
    ROIC (5Y Average)-46.54%
    Asset Turnover0.01x

    Scores

    ROIV has an Altman Z-Score of 44.45, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score44.45
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $41.08M over the last 12 months.

    Revenue$41.08M
    Revenue Growth (YoY)+102.09%
    Gross Profit$37.89M
    Operating Income-$557.96M
    Pretax Income-$297.18M
    Net Income-$385.77M
    Reported EPS (TTM)-$1.31

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 80.72% of the $4.98B in total assets.

    Cash and Equivalents$1.64B
    Total Debt$0
    Net Cash$1.64B
    Net Cash Per Share$2.27
    Working Capital$4.08B
    Shareholder Equity$4.02B
    Book Value Per Share$5.56
    Total Assets$4.98B
    Total Liabilities$380.10M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.82M of capital spending, operating cash flow left -$43.21M of free cash flow.

    Operating Cash Flow-$36.39M
    Capital Expenditures$6.82M
    Free Cash Flow-$43.21M
    FCF Per Share-$0.06
    Depreciation and Amortization$28.77M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1358.15%.

    Gross Margin92.23%
    Operating Margin-1358.15%
    Pretax Margin-723.38%
    Net Margin-939.03%
    FCF Margin-105.18%

    Growth

    Revenue fell 36.01% a year over 3 years.

    Revenue Growth (3Y CAGR)-36.01%
    Revenue Growth (5Y CAGR)-19.07%
    Book Value Per Share Growth (2Y CAGR)-13.41%
    Tangible Book Per Share Growth (2Y CAGR)-13.41%

    Revenue and profit by year

    Dividends and Yields

    ROIV does not pay a dividend. Its free cash flow yield is -0.15%.

    FCF Yield-0.15%
    Buyback Yield0.71%
    Shareholder Yield0.71%

    Peer Position

    Against 10 similar companies, ROIV has the highest P/S.

    P/S Ratio681.0x vs 14.7x median
    Revenue Growth (Trailing 4 Quarters, YoY)+102.09% vs +13.48% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 714.10% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+714.10%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ROIV

    What is ROIV's market cap?

    Roivant Sciences has a market cap of $28.64B. Its enterprise value, which adds debt and subtracts cash, is $27.00B.

    How many shares of ROIV are outstanding?

    Roivant Sciences has 722.75M shares outstanding. The count is up 6.14% from a year earlier.

    Does ROIV pay a dividend?

    No. Roivant Sciences does not pay a dividend.

    How much debt does ROIV have?

    Roivant Sciences has $0 of total debt and $1.64B of cash and equivalents, a net cash position of $1.64B.